Centiva Capital’s Co-Diagnostics CODX Stock Holding History

Centiva Capital’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-805	Closed	-$230K	–	1412
2021 Q1	$230K	Buy	+805	New	+$321K	0.01%	916

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ARC

Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Centiva Capital's CODX Position: Q2 2021 in Review

Centiva Capital sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 805 shares — an estimated $230K sold.

Centiva Capital first reported a position in CODX in Q1 2021 and held it in 1 quarter. The position peaked at $230K in Q1 2021. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

Centiva Capital reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
Centiva Capital sold 805 Co-Diagnostics shares in Q2 2021, an estimated $230K.
Centiva Capital first reported a position in Co-Diagnostics in Q1 2021 and held it in 1 quarter.
Centiva Capital's Co-Diagnostics position peaked at $230K in Q1 2021.
88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Centiva Capital's 13F filing for Q2 2021, filed 16 Aug 2021.